APA (7th ed.) Citation

T, G., HM, H., N, T., KL, S., R, D., C, C., . . . RA, F. (2026). Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases. Breast (Edinburgh, Scotland), 89, 104881. https://doi.org/10.1016/j.breast.2026.104881

Chicago Style (17th ed.) Citation

T, Grinda, et al. "Patient-reported Outcomes from the TBCRC 022 Study of Neratinib and Ado-trastuzumab Emtansine for HER2-positive Breast Cancer Brain Metastases." Breast (Edinburgh, Scotland) 89 (2026): 104881. https://doi.org/10.1016/j.breast.2026.104881.

MLA (9th ed.) Citation

T, Grinda, et al. "Patient-reported Outcomes from the TBCRC 022 Study of Neratinib and Ado-trastuzumab Emtansine for HER2-positive Breast Cancer Brain Metastases." Breast (Edinburgh, Scotland), vol. 89, 2026, p. 104881, https://doi.org/10.1016/j.breast.2026.104881.